anticancer/hemorrhage

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/KR2016/003451 filed Apr. 4, 2016, which in turn claims priority of Korean Patent Application No. 10-2015-0047329 filed Apr. 3,

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable. BACKGROUND OF THE INVENTION Hemostasis (the process of initiating blood coagulation in order to stop bleeding) may be abnormal and possibly life-threatening under a number of circumstances, yet there is a need for

TECHNICAL FIELD OF THE INVENTION This invention is related to the field of oncology. In particular it relates to combined biological and chemical treatments of tumors. BACKGROUND OF THE INVENTION Despite enormous progress in understanding the pathophysiology of neoplasia, advanced forms of cancer

DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The substance of the present invention is an antitumor-proteinaceous substance that is released into the culture supernatant by cultured cells such as mammalian cultured cells that are able to proliferate without any restriction and to

FIELD OF THE INVENTION The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin

FIELD OF THE INVENTION The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin

BACKGROUND OF THE INVENTION The present invention relates generally to the treatment of esophageal varices, and more particularly to a method and apparatus for applying sclerosant or thrombosant agents to esophageal varices. Further, the present invention relates to a method for the destruction of

BACKGROUND OF THE INVENTION The present invention relates generally to the treatment of esophageal varices, and more particularly to a method and apparatus for applying sclerosant or thrombosant agents to esophageal varices. Further, the present invention relates to a method for the destruction of

FIELD OF THE INVENTION The invention relates to therapeutic polypeptides useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, pro-hematopoietic (e.g., anemias, radiation or

3. FIELD OF THE INVENTION The invention relates to therapeutic polypeptides useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, pro-hematopoietic (e.g., anemias, radiation or

This is application is a nonprovisional of our co-pending U.S. application Ser. No. 60/007,888 filed Dec. 1, 1995, the disclosure of which is incorporated herein by reference. FIELD OF THE INVENTION The present invention relates generally to methods of using various gas carriers to enhance the

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable. BACKGROUND OF THE INVENTION Hemostasis (the process of initiating blood coagulation in order to stop bleeding) may be abnormal and possibly life-threatening under a number of circumstances, yet there is a need for

TECHNICAL FIELD The present invention relates to a pyridine derivative having an ability to act as a neurotrophic factor and a salt thereof. BACKGROUND ART It has been suggested that in Alzheimer's disease, which has recently been increasing in prevalence, degeneration and dysfunction of cholinergic